Twitter Inc (TWTR)’s Non-US Monetization Plans Are on Track

Twitter Inc (NYSE:TWTR) took a lot of time before it started taking monetization seriously. After its IPO, the second quarter earnings report for 2014, which it declared a few days ago, was its only quarter where it outperformed analyst expectations. Though most of its monetization efforts are currently concentrated in U.S., Twitter Inc (NYSE:TWTR) has a global user base which it will have to monetize someday in order to pose as a serious challenger to other tech behemoths. Adam Bain, President of Global Revenue & Partnerships at Twitter Inc (NYSE:TWTR), discussed the company’s growth and monetization efforts on CNBC, recently.

 twitter twtr facebook fb

“What we said in the last earning call, in Q2, is that monthly active user growth was incredibly strong for the quarter and what we started talking about is also this idea that one of the interesting thing about Twitter is that, things that happen on Twitter, don’t just stay on Twitter. They get distributed throughout the world into the apps, into the websites, even on TV and the like. So, we have started talking about how big this audience potential actually will be […],” Bain said.

Bain revealed that about 75% of Twitter Inc (NYSE:TWTR)’s users are based outside the United States, adding that Twitter Inc (NYSE:TWTR) has been a truly global company ever since its inception. Bain also revealed that the number of people who use Twitter Inc (NYSE:TWTR) without actually registering on the website can be as much as two to three times of the registered users.

According to Bain Twitter Inc (NYSE:TWTR) is new to the  monetization game as it started off just a couple of years ago. Bain also mentioned that in Asia Pacific and other reigons internationally the company has started to open its local offices only 12 to 18 months ago and from that perspective the growth of the company is really strong. He also highlighted that in second quarter of 2014, Twitter Inc (NYSE:TWTR)’s advertising revenues from outside U.S. saw an increase of 168% on the year.

Disclosure: None

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!